Nijhawan Pardeep 4

What Happened
Pardeep Nijhawan, CEO of Edesa Biotech (EDSA), acquired 153,550 common shares on June 16, 2026. The Form 4 reports the acquisition at $5.21 per share for an aggregate purchase price of $799,995.50 (rounded to $799,996). The transaction is reported on Form 4 as code "A" (grant/award/other acquisition) but a footnote clarifies this was a private placement purchase.

Key Details

• Transaction date: June 16, 2026
• Shares acquired: 153,550 at $5.21 per share
• Total cost reported: $799,995.50 (rounded to $799,996)
• Form transaction code: A (footnote states a private placement purchase)
• Shares owned after the transaction: not specified in the filing
• Notable footnotes:
  • F1: Confirms the private placement purchase and exact aggregate price.
  • F2 & F3: Several entities (two corporations and one trust) are related to Nijhawan; he disclaims beneficial ownership of securities held by those entities except to the extent of his pecuniary interest.
• Timeliness: Filed on the same date as the transaction (no late filing indicated).

Context
This was a direct private placement purchase (not an open-market trade), which can signal insider participation in a company financing or selective share issuance; however, the filing provides no details about resale restrictions, lock-ups, or the issuer's financing terms. As always, purchases are factual signals of insider buying but do not alone guarantee future stock performance.